This page identifies medical and regulatory publications that provide background information about cabozantinib, including its pharmacological properties, approved uses, dosage considerations, safety warnings, adverse reactions, and administration requirements.
The information is intended to support the educational content presented on this website. Official prescribing information and regulatory documents should always take priority when making clinical decisions.
1. United States Food and Drug Administration (FDA)
The FDA provides official prescribing information and regulatory documentation for approved cabozantinib products in the United States.
Reference 1: CABOMETYX Prescribing Information
- Product: CABOMETYX.
- Active ingredient: Cabozantinib.
- Dosage form: Tablets.
- Document type: FDA-approved prescribing information.
- Revision: October 2025.
- Publisher: United States Food and Drug Administration.
This document provides information about approved indications, dosage and administration, contraindications, warnings, precautions, adverse reactions, drug interactions, and use in specific populations.
Reference 2: COMETRIQ Prescribing Information
- Product: COMETRIQ.
- Active ingredient: Cabozantinib.
- Dosage form: Capsules.
- Document type: FDA-approved prescribing information.
- Revision: October 2025.
- Publisher: United States Food and Drug Administration.
This document provides formulation-specific information for cabozantinib capsules, including their approved indication for progressive metastatic medullary thyroid cancer, administration requirements, dosage, and safety considerations.
These two prescribing documents are important because cabozantinib tablets and capsules have different pharmaceutical characteristics and must not be substituted for one another.
2. DailyMed Drug Information
Reference 3: CABOMETYX Drug Label Information
- Medicine: Cabozantinib tablets.
- Product: CABOMETYX.
- Publisher: National Library of Medicine, United States.
- Source collection: DailyMed.
- Label update: October 19, 2025.
This reference provides detailed drug labeling information, including:
- Description of the medicine.
- Clinical pharmacology.
- Indications and usage.
- Dosage and administration.
- Warnings and precautions.
- Adverse reactions.
- Drug interactions.
- Use during pregnancy and breastfeeding.
- Patient counseling information.
DailyMed provides access to structured drug-label information submitted to the FDA.
3. European Medicines Agency (EMA)
Reference 4: CABOMETYX European Product Information
- Product: CABOMETYX.
- Active ingredient: Cabozantinib.
- Dosage form: Tablets.
- Publisher: European Medicines Agency.
- Document type: European product information.
This reference provides information about the European authorization and prescribing requirements for CABOMETYX.
Relevant topics include therapeutic indications, dosage, contraindications, special warnings, interactions, and adverse reactions.
Regulatory approvals and prescribing requirements may differ between the European Union and other countries.
4. Cabozantinib Clinical Pharmacology
Reference 5: Cabozantinib Mechanism of Action and Pharmacological Properties
Cabozantinib is a multi-targeted tyrosine kinase inhibitor.
Its pharmacological activity involves inhibition of several receptor tyrosine kinases, including:
- MET.
- VEGFR1.
- VEGFR2.
- VEGFR3.
- AXL.
- RET.
- KIT.
These molecular targets are involved in cellular growth, survival, migration, angiogenesis, and other biological processes associated with cancer development.
Official product prescribing information and clinical pharmacology documentation provide the basis for describing these mechanisms.
5. Clinical and Regulatory Information
Reference 6: Cabozantinib for Advanced Renal Cell Carcinoma
Regulatory and clinical documentation concerning cabozantinib use in selected patients with advanced renal cell carcinoma.
Reference 7: Cabozantinib for Hepatocellular Carcinoma
Clinical and regulatory information concerning cabozantinib use in patients with hepatocellular carcinoma who have received previous treatment with sorafenib.
Reference 8: Cabozantinib for Differentiated Thyroid Cancer
Regulatory documentation concerning cabozantinib tablets for eligible patients with advanced or metastatic differentiated thyroid cancer following specified previous treatment.
Reference 9: Cabozantinib for Neuroendocrine Tumors
FDA prescribing information updated in March 2025 includes an indication for specified previously treated, unresectable, locally advanced, or metastatic well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors.
Reference 10: Cabozantinib for Medullary Thyroid Cancer
Regulatory documentation concerning cabozantinib capsule treatment for progressive metastatic medullary thyroid cancer.
These references describe established treatment settings for specific cabozantinib formulations. They do not independently establish the approved indications of Caboxen.
6. Important Safety References
The following safety topics should be reviewed in the official prescribing information for the applicable cabozantinib formulation:
- Hemorrhage and bleeding complications.
- Gastrointestinal perforation and fistula formation.
- Arterial and venous thromboembolic events.
- Hypertension and hypertensive crisis.
- Diarrhea and dehydration.
- Palmar-plantar erythrodysesthesia.
- Hepatotoxicity.
- Proteinuria.
- Osteonecrosis of the jaw.
- Impaired wound healing.
- Reversible posterior leukoencephalopathy syndrome.
- Embryo-fetal toxicity.
The safety profile and monitoring requirements should be assessed individually by the prescribing healthcare professional.
7. Product-Specific Verification References
The following documentation should be obtained before publishing definitive product-specific claims about Caboxen:
- Official Caboxen product information.
- Manufacturer identification and documentation.
- Product registration or marketing authorization.
- Confirmed dosage form.
- Approved strength information.
- Batch and product identification details.
- Official storage and handling instructions.
- Product-specific prescribing information.
At present, the manufacturer, exact dosage form, and regulatory authorization of Caboxen have not been independently established in the information available for this website.
8. Reference Use and Medical Accuracy
The references listed above provide medical and regulatory background for cabozantinib.
The following principles apply when interpreting them:
- Reference product information must not automatically be applied to Caboxen.
- Tablet and capsule prescribing instructions must remain separate.
- Approved indications must be interpreted according to the relevant formulation and jurisdiction.
- Dosage information must be reviewed by qualified healthcare professionals.
- Safety information should be updated when official prescribing documents change.
- Product authenticity and regulatory status require independent verification.
Medical Reference Disclaimer
The references presented on this page are intended for educational purposes. They do not constitute an independent verification of Caboxen’s manufacturer, manufacturing quality, regulatory approval, or product authenticity.
Official regulatory documents and the applicable product-specific prescribing information should be consulted before prescribing or using cabozantinib.